Sign In
Buy EXEL
$56.00
+0.94 (+1.71%)
At Close: Aug 04, 2026
3 Top-Rated Biotech Stocks Wall Street Analysts Are Loving Now: January 2024
01:16pm, Sunday, 21'st Jan 2024
Stocks in the biotech sector are always going to have massive potential. Health is arguably the most important aspect of life.
Exelixis (EXEL) Reports Positive EU Patent Ruling for Cabometyx
12:26pm, Friday, 19'th Jan 2024
Exelixis (EXEL) gets a favorable ruling from the European Patent Office in a lawsuit related to its oral oncology drug, Cabometyx.
Exelixis (EXEL) Outperforms on Cabometyx and Pipeline Progress
12:31pm, Wednesday, 17'th Jan 2024
Exelixis' (EXEL) lead drug, Cabometyx, maintains momentum on consistent demand. Efforts to develop additional drugs to expand its portfolio are poised to reap rewards.
Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles
04:22am, Wednesday, 17'th Jan 2024
Exelixis Inc. is a biotech company focused on oncology, with its main products being Cometriq and Cabometyx, which are used for treating thyroid and kidney cancer. The company faces a legal battle aga
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
11:19am, Thursday, 11'th Jan 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Exelixis (EXEL) Posts Preliminary 2023 Results, to Cut 13% Jobs
02:17pm, Monday, 08'th Jan 2024
Exelixis (EXEL) posts preliminary results for 2023 and issues 2024 guidance. The company is set to cut its workforce by 13% in the first quarter of 2024.
Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024
04:05pm, Tuesday, 02'nd Jan 2024
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview
5 Biotech Acquisition Targets To Accumulate In 2024
01:05pm, Thursday, 21'st Dec 2023
Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provid
Is the Options Market Predicting a Spike in Exelixis (EXEL) Stock?
10:32am, Tuesday, 12'th Dec 2023
Investors need to pay close attention to Exelixis (EXEL) stock based on the movements in the options market lately.
Exelixis (EXEL) Collaborates With Arcus for Kidney Cancer Study
03:02pm, Tuesday, 05'th Dec 2023
Exelixis (EXEL) partners with Arcus Biosciences for a phase Ib/II study to evaluate zanzalintinib in combination with AB521 for ccRCC.
Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023
04:05pm, Tuesday, 21'st Nov 2023
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tu
Exelixis (EXEL) Gains 30% YTD on Cabometyx, Pipeline Progress
03:02pm, Friday, 17'th Nov 2023
Exelixis (EXEL) lead drug Cabometyx maintains momentum on consistent demand. Efforts to develop additional drugs to expand its portfolio are poised to reap rewards.
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow's Cures
04:43pm, Thursday, 09'th Nov 2023
In the fluctuating U.S. stock market, biotech stocks have faced challenges. The sector's most popular index, iShares Biotechnology ETF (NASDAQ: IBB ), is dropping 9% year to date (YTD).
3 Biotech Stocks With the Strongest Clinical Pipelines
05:24pm, Wednesday, 08'th Nov 2023
Biotech is still one of the most exciting sectors on the market. Recession-proof, the sector is still thriving with millions of retiring baby boomers, mergers and acquisitions, new innovation, the int
3 Promising Biotech Stocks Flying Under the Radar
05:19am, Wednesday, 08'th Nov 2023
Thanks to the biotechnology sector, the advances and improvement of processes within the health sector have been incredible. The impact with society and the contribution they make both directly and in
